Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)

  • Technology appraisal
  • TA1123
  • Published: 

Suggested remit: To appraise the clinical and cost effectiveness of Depemokimab within its marketing authorisation for treating rhinosinusitis.

This page was last updated: